A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

被引：1
|
作者：
Janni, W.
Sarosiek, T.
Pikiel, J.
Karaszewska, B.
Staroslawska, E.
Salat, C.
Caglevic, C.
Potemski, P.
Brain, E.
Briggs, K.
de Silvio, M.
Sapunar, F.
Papadimitriou, C.
机构：
[1] Klinikum Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[2] NZOZ Magodent, Ctr Med Ostrobramska, Warsaw, Poland
[3] Ctr Badan Klin, Wojewodzkie Ctr Onkol, Gdansk, Poland
[4] Przychodnia Lekarska NZOZ KOMED, Konin, Poland
[5] Ctr Onkol Ziemii Lubelskiej, Lublin, Poland
[6] Hamatoonkol Gemeinschaftspraxis, Munich, Germany
[7] Mariano Sanchez Fontecilla, Las Condes, Chile
[8] Wojewodzki Szpital Specjalistyczny, Kopernika, Poland
[9] Inst Curie, Hop Rene Huguenin, St Cloud, France
[10] GlaxoSmithKline Oncol, Uxbridge, Middx, England
[11] GlaxoSmithKline Oncol, Collegeville, PA USA
[12] Gen Hosp Athens, Therapeut Clin, Athens, Greece
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-21
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II randomized trail of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC)
    Janni, W.
    Alvarez, J. V.
    Papadimitriou, C. A.
    Karaszewska, B.
    Wiest, W.
    Lim, M. L.
    Das-Gupta, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results
    Janni, W.
    Sarosiek, T.
    Papadimitriou, C. A.
    Gallego, J. V. Alvarez
    Caruso, M.
    Wiest, W.
    Lim, M. L.
    Andersson, H.
    Das-Gupta, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).
    Papadimitriou, Christos A.
    Sarosiek, Tomasz
    Pikiel, Joanna
    Karaszewska, Boguslawa
    Salat, Christoph
    Caglevic, Christian
    Potemski, Piotr
    Brain, Etienne
    Briggs, Kathryn Jane
    DeSilvio, Michelle
    Marini, Luca
    Janni, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer.
    Janni, W.
    Pikiel, J.
    Sarosiek, T.
    Karaszewska, B.
    Papadimitriou, C. A.
    Schwedler, K.
    Alavarez, Gallego J.
    Caruso, M.
    Herve, R. A.
    Lau, M. R.
    Williams, L. S.
    Briggs, K.
    Sapunar, F. J.
    [J]. CANCER RESEARCH, 2011, 71
  • [5] Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer
    Chew, Helen K.
    Schwartzberg, Lee Steven
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James P.
    DeSilvio, Michelle
    Mahoney, Janine M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    [J]. SPRINGERPLUS, 2014, 3
  • [7] Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC)
    Blancas, I.
    Morales, S.
    Diaz, N.
    Barnadas, A.
    Gonzalvez, M. L.
    del Barco, S.
    Lopez de Ceballos, M. H.
    Perez, F. J.
    Llombart-Cussac, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A Phase I/II study of capecitabine (X) combined with oral vinorelbine IN) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Delcambre, C.
    Veyret, C.
    Levy, C.
    Switsers, O.
    Allouache, D.
    Raban, N.
    Grellard, J. M.
    Leconte, A.
    Delozier, T.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 118 - 118
  • [9] Adjuvant and neoadjuvant therapy with lapatinib in ErbB2-overexpressing breast cancer
    Janni, Wolfgang
    von Minckwitz, Gunter
    Moebus, Volker
    Nitz, Ulrike
    [J]. BREAST CARE, 2008, 3 : 17 - 20
  • [10] Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial
    U. O. Njiaju
    A. J. Tevaarwerk
    K. Kim
    J. E. Chang
    R. M. Hansen
    T. L. Champeny
    A. M. Traynor
    S. Meadows
    L. Van Ummersen
    K. Powers
    J. A. Stewart
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 71 : 613 - 618
12345